(Q45293374)

11 December 2017

title

From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors (English)

1 reference

11 December 2017

5

Gerhard Eisenbrand

1 reference

11 December 2017

Rolf Jautelat

1

1 reference

11 December 2017

Thomas Brumby

2

1 reference

11 December 2017

Martina Schäfer

3

1 reference

11 December 2017

Hans Briem

4

1 reference

11 December 2017

Stefan Schwahn

6

1 reference

11 December 2017

Martin Krüger

7

1 reference

11 December 2017

Ulrich Lücking

8

1 reference

11 December 2017

Olaf Prien

9

1 reference

11 December 2017

Gerhard Siemeister

10

1 reference

11 December 2017

language of work or name

1 reference

1 March 2005

1 reference

11 December 2017

1 reference

11 December 2017

volume

6

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

531-540

1 reference

Highlight on the studies of anticancer drugs derived from plants in China

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Small molecules as inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Solubility and partitioning I: Solubility of nonelectrolytes in water.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Property-based design: optimization of drug absorption and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

GSK-3-selective inhibitors derived from Tyrian purple indirubins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Aryl hydrocarbon receptor response to indigoids in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Kinase inhibitors: not just for kinases anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

Processing of X-ray diffraction data collected in oscillation mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

AMoRe: an automated package for molecular replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400108

21 January 2018

Identifiers

DOI

10.1002/CBIC.200400108

1 reference

11 December 2017

1 reference